Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Saved in:
| Title: | Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. |
|---|---|
| Authors: | Riek, Myriam1 (AUTHOR) myriam.riek@scqm.ch, Scherer, Almut1 (AUTHOR), Möller, Burkhard2 (AUTHOR), Ciurea, Adrian3 (AUTHOR), von Mühlenen, Ines4 (AUTHOR), Gabay, Cem5 (AUTHOR), Kyburz, Diego6 (AUTHOR), Brulhart, Laure7 (AUTHOR), von Kempis, Johannes8 (AUTHOR), Mueller, Ruediger B.9 (AUTHOR), Hasler, Paul10 (AUTHOR), Strahm, Tanja1 (AUTHOR), von Känel, Sabine1 (AUTHOR), Zufferey, Pascal11 (AUTHOR), Dudler, Jean12 (AUTHOR), Finckh, Axel5 (AUTHOR) |
| Source: | Scientific Reports. 11/18/2023, Vol. 13 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
